Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN)
CUSIP: 29337E102
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 58,923,077
- Total 13F shares
- 48,318,843
- Share change
- +3,854,076
- Total reported value
- $1,129,194,355
- Put/Call ratio
- 4.9%
- Price per share
- $23.37
- Number of holders
- 91
- Value change
- +$91,652,714
- Number of buys
- 65
- Number of sells
- 26
Quarterly Holders Quick Answers
What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29337E102:
Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
3/4/5
13F
|
Director, 10%+ Owner · Company |
15%
from 13F
|
7,663,349
|
$169,666,547 | — | 16 May 2024 | |
| FMR LLC |
13F
|
Company |
11%
|
6,246,293
|
$109,872,294 | — | 31 Mar 2024 | |
| VR Adviser, LLC |
13F
|
Company |
6.8%
|
4,026,331
|
$70,823,162 | — | 31 Mar 2024 | |
| Commodore Capital LP |
13F
3/4/5
|
Company · 10%+ Owner |
6.7%
|
3,973,245
|
$69,889,380 | — | 31 Mar 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
6.5%
|
3,835,975
|
$67,474,800 | — | 31 Mar 2024 | |
| David P. Bonita |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,207,568
mixed-class rows
|
$63,552,894 | — | 02 Jun 2022 | |
| 5AM Partners VI, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,835,975
|
$57,156,028 | — | 14 Feb 2024 | |
| Fairmount Funds Management LLC |
13F
|
Company |
5.4%
|
3,202,798
|
$56,337,217 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4%
|
2,354,403
|
$41,413,949 | — | 31 Mar 2024 | |
| New Enterprise Associates 14, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,611,050
|
$39,518,242 | — | 05 Apr 2022 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
3/4/5
|
Company · Former 10% owner |
3.6%
|
2,122,465
|
$37,334,159 | — | 31 Mar 2024 | |
| Mark Chin |
3/4/5
|
Director |
—
mixed-class rows
|
2,352,572
mixed-class rows
|
$35,477,530 | — | 02 Jun 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.1%
|
1,813,351
|
$31,896,844 | — | 31 Mar 2024 | |
| Braden M. Leonard |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,997,774
|
$30,236,309 | — | 03 Jan 2023 | |
| Logos Global Management LP |
13F
|
Company |
2.7%
|
1,574,220
|
$26,408,383 | — | 31 Mar 2024 | |
| Barbara Dalton |
3/4/5
|
Director |
—
mixed-class rows
|
1,566,222
mixed-class rows
|
$23,576,122 | — | 02 Jun 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
1,183,266
|
$20,813,649 | — | 31 Mar 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1.2%
|
713,911
|
$12,604,093 | — | 31 Mar 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
1.1%
|
671,358
|
$11,809,187 | — | 31 Mar 2024 | |
| Carl Goldfischer |
3/4/5
|
Director |
—
mixed-class rows
|
711,880
mixed-class rows
|
$10,645,656 | — | 02 Jun 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.83%
|
491,848
|
$8,651,606 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.81%
|
475,456
|
$8,364,131 | — | 31 Mar 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.73%
|
428,571
|
$7,538,564 | — | 31 Mar 2024 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.67%
|
396,099
|
$6,967,381 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.67%
|
395,686
|
$6,960,117 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.37%
|
218,758
|
$3,847,953 | — | 31 Mar 2024 | |
| David M. Mott |
3/4/5
|
Director |
—
mixed-class rows
|
237,724
mixed-class rows
|
$3,469,305 | — | 02 Jun 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.27%
|
159,035
|
$2,797,426 | — | 31 Mar 2024 | |
| HighVista Strategies LLC |
13F
|
Company |
0.22%
|
126,854
|
$2,231,362 | — | 31 Mar 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.19%
|
114,833
|
$2,019,912 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.14%
|
82,995
|
$1,459,882 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.13%
|
76,477
|
$1,345,231 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.11%
|
63,097
|
$1,109,876 | — | 31 Mar 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
0.1%
|
57,635
|
$1,013,800 | — | 31 Mar 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.1%
|
56,763
|
$998,461 | — | 31 Mar 2024 | |
| BML Capital Management, LLC |
13F
|
Company |
0.09%
|
50,100
|
$881,259 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.06%
|
38,207
|
$672,051 | — | 31 Mar 2024 | |
| Swiss National Bank |
13F
|
Company |
0.06%
|
36,773
|
$646,837 | — | 31 Mar 2024 | |
| Kenneth Attie |
3/4/5
|
SVP, CMO |
—
mixed-class rows
|
68,200
mixed-class rows
|
$516,104 | — | 28 Jan 2022 | |
| Diametric Capital, LP |
13F
|
Company |
0.05%
|
29,284
|
$515,105 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
26,835
|
$472,027 | — | 31 Mar 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.04%
|
26,236
|
$461,492 | — | 31 Mar 2024 | |
| Blackstone Inc. |
13F
|
Company |
0.04%
|
25,191
|
$443,110 | — | 31 Mar 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.04%
|
25,000
|
$439,750 | — | 31 Mar 2024 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
0.04%
|
24,691
|
$434,315 | — | 31 Mar 2024 | |
| Michael Gray |
3/4/5
|
CFO & COO |
—
class O/S missing
|
27,610
|
$417,877 | — | 22 Feb 2023 | |
| CREDIT SUISSE AG/ |
13F
|
Company |
0.04%
|
21,895
|
$385,133 | — | 31 Mar 2024 | |
| Legal & General Group Plc |
13F
|
Company |
0.04%
|
20,645
|
$363,318 | — | 31 Mar 2024 | |
| NEW YORK LIFE INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.03%
|
20,249
|
$356,180 | — | 31 Mar 2024 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.03%
|
19,141
|
$336,690 | — | 31 Mar 2024 |
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) as of Q2 2024
As of 30 Jun 2024,
Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) was held by
91 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,318,843 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, FMR LLC, VR Adviser, LLC, COMMODORE CAPITAL LP, Fairmount Funds Management LLC, BlackRock Inc., 5AM Venture Management, LLC, CITADEL ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., and VANGUARD GROUP INC.
This page lists
91
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
72
Q2 2024 holders
91
Holder diff
19
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.